ストックスクリーナーアプリを入手
2.85
3.06%
-0.09
アフターアワーズ：
2.73
-0.12
-4.21%
前日終値:
$2.94
開ける：
$2.93
24時間の取引高:
97,015
Relative Volume:
0.10
時価総額：
$62.68M
収益：
$14.79M
当期純損益:
$-181.41M
株価収益率:
-5.8163
EPS:
-0.49
ネットキャッシュフロー:
$-68.18M
1週間 パフォーマンス:
+26.67%
1か月 パフォーマンス:
+35.39%
6か月 パフォーマンス:
-5.63%
1年 パフォーマンス:
+39.23%
1日の値動き範囲:
$2.72
$2.9799
1週間の範囲:
$2.1183
$3.70
52週間の値動き範囲:
$1.30
$7.97
Celularity Inc Stock (CELU) Company Profile
CELU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CELU | 2.85 | 62.68M | 14.79M | -181.41M | -68.18M | -0.49 |
| VRTX | 450.37 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-01-30 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 開始されました | H.C. Wainwright | Buy |
| 2022-04-06 | ダウングレード | Truist | Buy → Hold |
| 2022-01-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-24 | 開始されました | Morgan Stanley | Equal-Weight |
すべてを表示
Celularity Inc (CELU) 最新ニュース
Celularity Partners with Genting to Build $7.2B Market-Targeting Stem Cell Facility in Bali | CELU Stock News - StockTitan
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter - The Manila Times
Celularity Resolves Nasdaq Compliance Issue, Maintains Listing After Filing Reports | CELU Stock News - StockTitan
Celularity Inc. (NASDAQ:CELU) Sees Large Increase in Short Interest - MarketBeat
After-Market Momentum: Celularity (CELU) Shares Climb On Increased Guidance - Stocks Telegraph
Celularity sets annual meeting date, stockholder proposal deadline By Investing.com - Investing.com Canada
Celularity sets annual meeting date, stockholder proposal deadline - Investing.com India
Celularity Inc. (CELU) Quarterly 10-Q Report - Quartzy
Celularity Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
U.S. Stock market: Celularity(+52.68%), Applovin(+45.14%), FARO Technologies(+33.01%) and others were among the top gainers during mid day trading - Business Upturn
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million - The Manila Times
Celularity Raises 2024 Sales Forecast to $60M After Record-Breaking October Revenue | CELU Stock News - StockTitan
CELU stock touches 52-week low at $1.55 amid market fluctuations - Investing.com India
CELU stock touches 52-week low at $1.55 amid market fluctuations By Investing.com - Investing.com South Africa
Celularity reports over $24 million in biomaterial revenue By Investing.com - Investing.com Australia
Celularity Inc. Announces Anticipated Revenues for Second and Third Quarters - Defense World
Celularity reports over $24 million in biomaterial revenue - Investing.com India
Celularity Receives Nasdaq Delisting Notice Over Filing Delay - Marketscreener.com
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel - The Manila Times
Celularity reports progress on Nasdaq compliance and product sales - Investing.com
Celularity reports progress on Nasdaq compliance and product sales By Investing.com - Investing.com Australia
Celularity Provides Corporate Update - citybiz
CELUWCelularity Inc. Warrant Latest Stock News & Market Updates - StockTitan
Celularity to submit 510(k) notification for Tendon Wrap in early 2025 - TipRanks
Celularity faces Nasdaq delisting over reporting delays - Investing.com
Celularity faces Nasdaq delisting over reporting delays By Investing.com - Investing.com UK
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal - ForexTV.com
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc. - The Manila Times
Celularity expands biomaterials range with Rebound acquisition - Investing.com India
Celularity Inc SEC 10-Q Report - TradingView
Stem Cell Umbilical Cord Blood Market Report 2024, with Profiles of Cryo-Cell, Cordlife, ViaCord, CryoHoldco, LifeCell, StemCyte, Celularity Cryo-Save and Vita 34 - Yahoo Finance
Celularity (NASDAQ:CELU) Stock Price Down 8.8%Should You Sell? - MarketBeat
Amniotic Membrane Market to Grow by USD 2.7 Billion (2024-2028) with AI Impact Boosting Trends in Ophthalmic Surgery UseTechnavio Report - The Malaysian Reserve
BTIG maintains Buy rating on Cullinan Oncology stock - Investing.com
Cullinan Oncology maintains Buy rating from H.C. Wainwright with steady price target - Investing.com India
Trend Tracker for (CLS) - Stock Traders Daily
Cullinan Therapeutics (NASDAQ:CGEM) Earns Outperform Rating from Wedbush - MarketBeat
Caesars Entertainment Inc (CZR) stock: A year of ups and downs - US Post News
In the Green: Cerus Corp. (CERS) Closes at 1.97, Up/Down -4.37 from Previous Day - The Dwinnex
Creo Medical to get £25m boost from majority sale of its European business - Business Live
Medical device company to sell stake of subsidiary to Chinese manufacturerequity value of €72m - Insider Media
Objective long/short (CGEM) Report - Stock Traders Daily
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA - Yahoo Finance
Cullinan Therapeutics Inc (CGEM)’s stock price in review: A technical analysis - US Post News
(CELC) Technical Pivots with Risk Controls - Stock Traders Daily
Creo Medical Partners with Micro-Tech for Strategic Growth - TipRanks
E Fund Management Co. Ltd. Purchases New Shares in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - MarketBeat
State of New Jersey Common Pension Fund D Has $3.31 Million Stock Holdings in Caesars Entertainment, Inc. (NASDAQ:CZR) - Defense World
Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com - MarketBeat
Cullinan Therapeutics commences Phase 1 trial for lupus treatment By Investing.com - Investing.com Canada
Celularity Inc (CELU) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
3.56%
大文字化:
|
ボリューム (24 時間):